Click here to discover the next stock our government trade tracker is spotlighting—before it takes off. Tonix Pharmaceuticals ... TNXP has a 52-week high of $1,146.01 and a 52-week low of ...

A copy of the Company’s poster will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be ...

In the assessment of 12-month price targets, analysts unveil insights for Collegium Pharmaceutical, presenting an average target of $45.5, a high ... stocks. Some analysts publish their ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 32.48%, which has investors questioning if this is right time to sell.

as evidenced by the stock's significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix Pharmaceuticals and offer a new treatment option for ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Investors have responded positively to the news, as evidenced by the stock’s significant rise in the trading session. If TNX-102 SL receives approval, it could mark a major milestone for Tonix ...

Tonix Pharmaceuticals (NASDAQ ... If this drug is not approved for these patients, then it will likely cause the stock price to trade significantly lower. Although, depending upon what is stated ...